Therefore, the disruption of glycolytic progression by inhibiting the activity of key glycolytic regulatory enzymes, including pyruvate kinase M2 (PKM2) [15] and lactate dehydrogenase A (LDHA) [16], has become a novel direction in the development of anti-cancer drugs. The gene discussed is LDHA; the disease is cancer.